1. Conjugation of a peptide to an antibody engineered with free cysteines dramatically improves half-life and activity
- Author
-
Raul C. Camacho, Seohee You, Katharine E. D’Aquino, Wenyu Li, Yuanping Wang, Joseph Gunnet, James Littrell, Jian Shen Qi, Lijuan Kang, Wenying Jian, Mary MacDonald, Timothy Tat, Derek Steiner, Yue-Mei Zhang, James Lanter, Raymond Patch, Rui Zhang, Jiali Li, Suzanne Edavettal, Wilson Edwards, Thai Dinh, Li Ying Wang, Judy Connor, Michael Hunter, Ellen Chi, Ronald V. Swanson, James N. Leonard, and Martin A. Case
- Subjects
Antibody-peptide conjugates ,GPCR agonists ,oxyntomodulin ,half-life extension ,Therapeutics. Pharmacology ,RM1-950 ,Immunologic diseases. Allergy ,RC581-607 - Abstract
The long circulating half-life and inherently bivalent architecture of IgGs provide an ideal vehicle for presenting otherwise short-lived G-protein-coupled receptor agonists in a format that enables avidity-driven enhancement of potency. Here, we describe the site-specific conjugation of a dual agonist peptide (an oxyntomodulin variant engineered for potency and in vivo stability) to the complementarity-determining regions (CDRs) of an immunologically silent IgG4. A cysteine-containing heavy chain CDR3 variant was identified that provided clean conjugation to a bromoacetylated peptide without interference from any of the endogenous mAb cysteine residues. The resulting mAb-peptide homodimer has high potency at both target receptors (glucagon receptor, GCGR, and glucagon-like peptide 1 receptor, GLP-1R) driven by an increase in receptor avidity provided by the spatially defined presentation of the peptides. Interestingly, the avidity effects are different at the two target receptors. A single dose of the long-acting peptide conjugate robustly inhibited food intake and decreased body weight in insulin resistant diet-induced obese mice, in addition to ameliorating glucose intolerance. Inhibition of food intake and decrease in body weight was also seen in overweight cynomolgus monkeys. The weight loss resulting from dosing with the bivalently conjugated dual agonist was significantly greater than for the monomeric analog, clearly demonstrating translation of the measured in vitro avidity to in vivo pharmacology.
- Published
- 2020
- Full Text
- View/download PDF